ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 14 No. 3 (2021), NEWS
Vol. 14 No. 3 (2021)
NEWS

AstraZeneca company press-release

Published 01.07.2021
PDF_2021-14-3-391-393 (Russian)

How to Cite

AstraZeneca company press-release. Clinical Oncohematology. 2021;(3):391–393. doi:10.21320/.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistics

Annotation views: 12
PDF_2021-14-3-391-393 (Russian) downloads: 2

Keywords

Abstract

AstraZeneca company press-release

PDF_2021-14-3-391-393 (Russian)

References

  1. NICE Guidance. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Available from: https://www.nice.org.uk/guidance/ta429/resources/ibrutinib-for-previously-treated-chronic-lymphocytic-leukaemia-and-untreated-chronic-lymphocytic-leukaemia-with-17p-deletion-or-tp53-mutation-pdf-82604672090053 (accessed 30.03.2021).
  2. Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). Available from: https://lymphoma-action.org.uk/types-lymphoma/chronic-lymphocytic-leukaemia-cll-and-small-lymphocytic-lymphoma-sll#:~:text=Around%203%2C500%20to%204%2C000%20people,is%20rare%20in%20young%20people (accessed 30.03.2021).
  3. Cancer Research UK. Cancer Statistics: CLL. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll#heading-One (accessed 30.03.2021).
  4. Calquence 100 mg hard capsules (package insert). Available from: https://www.medicines.org.uk/emc/product/11917/smpc (accessed 30.03.2021).
  5. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version. Available from: www.cancer.gov/types/leukemia/patient/cll-treatment-pdq (accessed 30.03.2021).
  6. Survival Rates and Outlook for Chronic Lymphocytic Leukemia. Available from: https://www.healthline.com/health/chronic-lymphocytic-leukemia-outlook#survival-rate (accessed 30.03.2021).
  7. The Emotional Impact of Watch and Wait for CLL. EHA 2019 poster. Available from: https://media.leukaemiacare.org.uk/wp-content/uploads/The-Emotional-Impact-of-Watch-and-Wait-for-CLL-EHA-2019-Poster.pdf (accessed 30.03.2021).
  8. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(1):21. doi: 10.1186/s13045-016-0250-9.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2021 Clinical Oncohematology